

# Global Synovial Sarcoma Drugs and Companies Pipeline Review H2 2016

*Synovial Sarcoma Treatment Pipeline Review H2 2016*

PUNE, INDIA, September 19, 2016 /EINPresswire.com/ -- [Synovial Sarcoma](#) - Pipeline Review, H2 2016

## Summary

'Synovial Sarcoma - Pipeline Review, H2 2016', provides an overview of the Synovial Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects.

Complete report details @

<https://www.wiseguyreports.com/reports/643486-synovial-sarcoma-pipeline-review-h2-2016> □



Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/643486-synovial-sarcoma-pipeline-review-h2-2016> □

## Scope

- The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
- The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma
- Reasons to buy
  - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  - Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
  - Identify potential new clients or partners in the target demographic
  - Develop strategic initiatives by understanding the focus areas of leading companies
  - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  - Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
  - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/643486-synovial-sarcoma-pipeline-review-h2-2016> □

## Key Points in Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Synovial Sarcoma Overview 8

Therapeutics Development 9

Pipeline Products for Synovial Sarcoma - Overview 9

Pipeline Products for Synovial Sarcoma - Comparative Analysis 10

Synovial Sarcoma - Therapeutics under Development by Companies 11

Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 12

Synovial Sarcoma - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Synovial Sarcoma - Products under Development by Companies 16

Synovial Sarcoma - Products under Investigation by Universities/Institutes 17

Synovial Sarcoma - Companies Involved in Therapeutics Development 18

Adaptimmune Therapeutics Plc 18

Advenchen Laboratories, LLC 19

EpiZyme, Inc. 20

Immune Design Corp. 21

Immunocore Limited 22

Karyopharm Therapeutics, Inc. 23

Merck & Co., Inc. 24

Millennium Pharmaceuticals Inc 25  
Novartis AG 26  
OncoTherapy Science, Inc. 27  
Pfizer Inc. 28  
Takara Bio Inc. 29  
Synovial Sarcoma - Therapeutics Assessment 30  
Assessment by Monotherapy Products 30  
Assessment by Target 31  
Assessment by Mechanism of Action 33  
Assessment by Route of Administration 35  
Assessment by Molecule Type 37  
Drug Profiles 39  
ACXT-3102 - Drug Profile 39  
Product Description 39  
Mechanism Of Action 39  
R&D Progress 39  
AL-3818 - Drug Profile 40  
Product Description 40  
Mechanism Of Action 40  
R&D Progress 40  
axitinib - Drug Profile 43  
Product Description 43  
Mechanism Of Action 43  
R&D Progress 43  
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 49  
Product Description 49  
Mechanism Of Action 49  
R&D Progress 49  
CMB-305 - Drug Profile 50  
Product Description 50  
Mechanism Of Action 50  
R&D Progress 50  
everolimus - Drug Profile 53  
Product Description 53  
Mechanism Of Action 53  
R&D Progress 53  
GSK-3377794 - Drug Profile 65  
Product Description 65  
Mechanism Of Action 65  
R&D Progress 65  
OTSA-101 - Drug Profile 71  
Product Description 71  
Mechanism Of Action 71  
R&D Progress 71  
pembrolizumab - Drug Profile 72  
Product Description 72  
Mechanism Of Action 72  
R&D Progress 72  
Recombinant Protein for Oncology - Drug Profile 103  
Product Description 103  
Mechanism Of Action 103  
R&D Progress 103  
Recombinant Proteins 1 for Oncology - Drug Profile 104  
Product Description 104  
Mechanism Of Action 104

R&D Progress 104  
sapanisertib - Drug Profile 105  
Product Description 105  
Mechanism Of Action 105  
R&D Progress 105  
selinexor - Drug Profile 108  
Product Description 108  
Mechanism Of Action 108  
R&D Progress 108  
SSTC-104 - Drug Profile 125  
Product Description 125  
Mechanism Of Action 125  
R&D Progress 125  
tazemetostat - Drug Profile 126  
Product Description 126

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=643486](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643486)

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.